145 related articles for article (PubMed ID: 3486715)
21. Growth inhibition of murine colonic adenocarcinoma by tumor immune but not by IL-2-activated or alloactivated lymphocytes.
Rodolfo M; Parmiani G
Tumori; 1987 Feb; 73(1):1-9. PubMed ID: 3493573
[TBL] [Abstract][Full Text] [Related]
22. [Effect of biological response modifiers on a spontaneous murine renal cell carcinoma regression of metastases caused by the streptococcal preparation OK-432].
Tanji S
Nihon Hinyokika Gakkai Zasshi; 1991 May; 82(5):716-25. PubMed ID: 1875566
[TBL] [Abstract][Full Text] [Related]
23. Radiation therapy enhances the therapeutic effect of immunotherapy on pulmonary metastases in a murine renal adenocarcinoma model.
Chakrabarty A; Hillman GG; Maughan RL; Ali E; Pontes JE; Haas GP
In Vivo; 1994; 8(1):25-31. PubMed ID: 8054507
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes.
Chen J; Niu H; He W; Ba D
Int Arch Allergy Immunol; 2001 Jul; 125(3):256-63. PubMed ID: 11490159
[TBL] [Abstract][Full Text] [Related]
26. Chemoimmunotherapy of metastatic murine renal cell carcinoma using flavone acetic acid and interleukin 2.
Salup RR; Sicker DC; Wolmark N; Herberman RB; Hakala TR
J Urol; 1992 Apr; 147(4):1120-3. PubMed ID: 1552607
[TBL] [Abstract][Full Text] [Related]
27. Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma.
Younes E; Haas GP; Dezso B; Ali E; Maughan RL; Kukuruga MA; Montecillo E; Pontes JE; Hillman GG
Cell Immunol; 1995 Oct; 165(2):243-51. PubMed ID: 7553889
[TBL] [Abstract][Full Text] [Related]
28. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
30. Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.
Gregorian SK; Battisto JR
Cancer Immunol Immunother; 1990; 31(6):325-34. PubMed ID: 2386978
[TBL] [Abstract][Full Text] [Related]
31. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
[TBL] [Abstract][Full Text] [Related]
32. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive cytolytic T cells for treatment of established mouse Renca tumors.
Qin W; Tian F; Wang F; Song B; Wang H; Zhang Q; Jovanovic B; Liang L; Guo Y; Smith N; Lee C
Urology; 2008 Oct; 72(4):943-7. PubMed ID: 18723212
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.
Melder RJ; Osborn BL; Riccobene T; Kanakaraj P; Wei P; Chen G; Stolow D; Halpern WG; Migone TS; Wang Q; Grzegorzewski KJ; Gallant G
Cancer Immunol Immunother; 2005 Jun; 54(6):535-47. PubMed ID: 15592670
[TBL] [Abstract][Full Text] [Related]
34. Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model.
Rodolfo M; Salvi C; Bassi C; Parmiani G
Cancer Immunol Immunother; 1990; 31(1):28-36. PubMed ID: 2306753
[TBL] [Abstract][Full Text] [Related]
35. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
36. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
[TBL] [Abstract][Full Text] [Related]
37. Role of IL-2, IL-4 and IL-6 in the growth and differentiation of tumor-specific CD4+ T helper and CD8+ T cytotoxic cells.
Selvan RS; Nagarkatti PS; Nagarkatti M
Int J Cancer; 1990 Jun; 45(6):1096-104. PubMed ID: 1972141
[TBL] [Abstract][Full Text] [Related]
38. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12.
Tannenbaum CS; Wicker N; Armstrong D; Tubbs R; Finke J; Bukowski RM; Hamilton TA
J Immunol; 1996 Jan; 156(2):693-9. PubMed ID: 8543822
[TBL] [Abstract][Full Text] [Related]
39. Cerebrovascular effects and tumor kinetics after a single intratumoral injection of human recombinant interleukin-2 alone or in combination with intravenous chemotherapy in a rat model of glioma.
Watts RG; Merchant RE
Neurosurgery; 1992 Jul; 31(1):89-98; discussion 98-9. PubMed ID: 1641114
[TBL] [Abstract][Full Text] [Related]
40. Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
Fan K; Zhou M; Pathak MK; Lindner DJ; Altuntas CZ; Tuohy VK; Borden EC; Yi T
J Immunol; 2005 Nov; 175(10):7003-8. PubMed ID: 16272361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
